Edoxaban for treating and for preventing deep vein thrombosis and pulmonary embolism

Deep vein thrombosis, pulmonary embolism (treatment, secondary prevention) - edoxaban tosylate [ID662]: equality impact assessment - guidance review

Deep vein thrombosis, pulmonary embolism (treatment, secondary prevention) - edoxaban tosylate [ID662]: final appraisal determination information

Deep vein thrombosis, pulmonary embolism (treatment, secondary prevention) - edoxaban tosylate [ID662]: final appraisal document

Deep vein thrombosis, pulmonary embolism (treatment, secondary prevention) - edoxaban tosylate [ID662]: final appraisal document (PDF 441 KB)

Deep vein thrombosis, pulmonary embolism (treatment, secondary prevention) - edoxaban tosylate [ID662]: committee papers information

Deep vein thrombosis, pulmonary embolism (treatment, secondary prevention) - edoxaban tosylate [ID662]: final scope

Deep vein thrombosis, pulmonary embolism (treatment, secondary prevention) - edoxaban tosylate [ID662]: final matrix

Deep vein thrombosis, pulmonary embolism (treatment, secondary prevention) - edoxaban tosylate [ID662]: NICE response to comments on the draft scope and provisional matrix

Deep vein thrombosis, pulmonary embolism (treatment, secondary prevention) - edoxaban tosylate [ID662]: equality impact assessment - scoping

Deep vein thrombosis, pulmonary embolism (treatment, secondary prevention) - edoxaban tosylate: draft scope for consultation (pre-referral) - March 2014 

Deep vein thrombosis, pulmonary embolism (treatment, secondary prevention) - edoxaban tosylate: provisional matrix (pre-referral) - March 2014